TITLE

Efficacy of Group Behavioral Activation Treatment as Supplemental Treatment to Pharmacotherapy in Inpatients with Depressive Disorders

AUTHOR(S)
Fereidooni, Samad; Gharaei, Banafsheh; Birashk, Behrooz; Sahraeian, Ali; Davood Hoseini, Seyed Mohammad
PUB. DATE
September 2015
SOURCE
Journal of Mood Disorders;2015, Vol. 5 Issue 3, p104
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Efficacy of group behavioral activation treatment as supplemental treatment to pharmacotherapy in inpatients with depressive disorders Objective: It is important to consider history of dealing with depression as it evolved from pure behavioral approaches that predate behavioral activation. Current behavioral activation adds an idiographic and functional approaches, which explores client's needs, goals and environmental contingencies that support depressive behaviors and moods. The aim of this study is to evaluate efficacy of Group Behavioral Activation Treatment (GBAT) as a supplemental treatment to pharmacotherapy in inpatients suffering from depressive disorders. Methods: This is a clinical trial. We included 24 patients with depressive disorders (according to SCID-I), who were admitted to Shiraz Psychiatric Hospital in summer 2010. They were randomly divided into three groups: intervention, control, and placebo. All three groups prescribed their usual pharmacological treatment. Additionally, first group was treated with GBAT. In order to control the efficacy of therapist's attention, third group watched video-movie as well. All participants completed Beck Depression Inventory-II (BDI-II) and Behavioral Activation for Depression Scale (BADS). Results: According to the results of the analysis of variance for repeated measures: all 3 groups showed same decrease in post and 2 mounts follow-up in BDI-II, however there was no significant difference among groups. Nevertheless, based on the results of analysis for BDI-II, it is indicated that behavioral activation therapy has been effective in decreasing depression of patients (F=11.27; p=0.001). Results indicated that based on the analysis of BADS, patients' depression has significantly decreased (F=105.97; p=0.001). Conclusions: Our research findings indicate that using the GBAT as a supplemental treatment for depressed inpatients can increase the effectiveness of medication therapy. Small sample size and cautions in the generalization of the present findings to be noted.
ACCESSION #
110103970

 

Related Articles

  • What is the State of the Evidence? Thase, Michael E. // Psychiatric Annals;Dec2003, Vol. 33 Issue 12, p813 

    Discusses therapeutic alternatives for difficult-to-treat depression. Treatment algorithms and practice guidelines; Definitions of treatment resistance; Antidepressant combinations that may be utilized.

  • Pharmacogenetics—A Useful Tool in Antidepressant Pharmacotherapy? Domschke, Katharina // Child & Adolescent Psychopharmacology News;2008, Vol. 13 Issue 4, p1 

    The article discusses the importance of treatment resistance and treatment intolerance in the pharmacotherapy of major depressive disorder (MDD). About 30%-40% of all patients fail to respond sufficiently to initial pharmacotherapy. Since it could take several weeks after treatment initiation to...

  • Treating depression in children and adolescents: what options now? Varley, Christopher K. // CNS Drugs;2006, Vol. 20 Issue 1, p1 

    There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage...

  • Cosmetic Psychopharmacology: The Ethics of Antidepressant Therapy. Kamara, Fareed B. // UBC Medical Journal;2014, Vol. 5 Issue 2, p17 

    Antidepressant medication, a commonly prescribed antidote for the depressed mood, continues to prove its value in primary and psychiatric health care. Its popularity in society requires its administrators and users to reflect on its function not only as a mood enhancer, but also as a modifier of...

  • Treating Suicidality in Depressive Illness. Part 2: Does Treatment Cure or Cause Suicidality? Sakinofsky, Isaac // Canadian Journal of Psychiatry;Jun2007 Supplement 1, Vol. 52, p85S 

    Objective: To systematically review studies of treatment efficacy for suicidality in mood disorders. To consider the evidence for whether antidepressants may induce suicidality. Method: Systematic review of the literature. Results and Conclusions: There is fairly good evidence that lithium...

  • Investigation of Antidepressant Medication Usage after Bariatric Surgery. Cunningham, Julie; Merrell, Cory; Sarr, Michael; Somers, Kristin; McAlpine, Donald; Reese, Michael; Stevens, Susanna; Clark, Matthew // Obesity Surgery;Apr2012, Vol. 22 Issue 4, p530 

    Background: Many patients seeking bariatric surgery have a history of mood disorders and are actively prescribed antidepressants. While extensive documentation exists on the impact of weight loss surgery on reductions in cardiac, diabetic, and hypertensive medications, little is known about the...

  • Tetrahydrobiopterin Pathway may Provide Novel Molecular Targets for Acute and Long Term Efficacy of Mood-Regulating Drugs. McHugh, Patrick C. // Current Pharmacogenomics & Personalized Medicine;Sep2010, Vol. 8 Issue 3, p174 

    Existing treatments for depression usually take several weeks to achieve their antidepressant effects, and a significant number of patients do not have adequate improvement or are treatment refractory even after long-term drug administration. Moreover, the increased risk of suicide is a serious...

  • Dothiepin-induced transient hypomania and extrapyramidal syndrome. Inamdar, Amir; Agarwal, Ashish; Kataria, Pankaj; Beniwal, R. P. // Indian Journal of Psychiatry;Oct-Dec2013, Vol. 55 Issue 4, p383 

    A case has been reported here, who developed transient hypomanic symptoms as well as extrapyramidal symptoms after being switched from sertraline to dothiepin therapy. The possible mechanisms and clinical implications of the same are discussed.

  • Late Onset Clozapine Induced Agranulocytosis. Velayudhan, Rajmohan; Kakkan, Sushil // Indian Journal of Psychological Medicine;Oct-Dec2014, Vol. 36 Issue 4, p425 

    Agranulocytosis is defined as an absolute neutrophil count less than 100/mm3 in association with infectious disease. The risk of agranulocytosis is 0.38% of all clozapine treated cases and there is a relatively lesser incidence in Indian population. The risk of clozapine-induced agranulocytosis...

  • Review: antidepressants increase clinical response and remission in bipolar depression without increasing induction of mania. Simon, Gregory E. // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p45 

    The article cites a research study, which revealed that antidepressants increase clinical response and remission in bipolar depression without increasing induction of mania. The researchers concluded that in patients with bipolar depression, antidepressants increase clinical response and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics